Nevertheless, our team has previously shown in vivo, in patient-derived xenografts (PDXs), that irinotecan administered at low doses has a cytotoxic or cytostatic effect without inducing genotoxic lesions, but rather by inhibiting the accumulation of HIF-1α protein and abolishing tumor vascularization [20]. Here, HIF1A is linked to neoplasm.